5AM Venture Management
Latest statistics and disclosures from 5AM Venture Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ELVN, TRDA, PHVS, CLDX, MLTX, and represent 52.61% of 5AM Venture Management's stock portfolio.
- Added to shares of these 6 stocks: BHVN (+$17M), MRUS (+$14M), CLDX (+$7.4M), PHVS (+$5.9M), VRDN, TYRA.
- Started 2 new stock positions in MRUS, BHVN.
- Reduced shares in these 5 stocks: CRNX (-$14M), IRON (-$8.3M), ARVN (-$6.3M), IMPLQ, MLTX.
- Sold out of its positions in ARVN, CRNX, IMPLQ.
- 5AM Venture Management was a net buyer of stock by $20M.
- 5AM Venture Management has $377M in assets under management (AUM), dropping by 8.47%.
- Central Index Key (CIK): 0001799883
Tip: Access up to 7 years of quarterly data
Positions held by 5AM Venture Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for 5AM Venture Management
5AM Venture Management holds 25 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Enliven Therapeutics (ELVN) | 18.9 | $71M | 5.2M | 13.84 |
|
|
Entrada Therapeutics (TRDA) | 17.6 | $67M | 4.4M | 15.09 |
|
|
Pharvaris N V (PHVS) | 5.9 | $22M | +35% | 798k | 28.05 |
|
Celldex Therapeutics Com New (CLDX) | 5.2 | $20M | +60% | 497k | 39.66 |
|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 4.8 | $18M | -3% | 303k | 60.39 |
|
Biohaven (BHVN) | 4.5 | $17M | NEW | 400k | 42.80 |
|
Disc Medicine (IRON) | 4.5 | $17M | -32% | 294k | 57.76 |
|
Dianthus Therapeutics (DNTH) | 4.1 | $15M | 1.5M | 10.40 |
|
|
Merus N V (MRUS) | 3.8 | $14M | NEW | 522k | 27.50 |
|
Vor Biopharma (VOR) | 3.8 | $14M | 6.4M | 2.25 |
|
|
Miragen Therapeutics (VRDN) | 3.4 | $13M | +43% | 587k | 21.78 |
|
Mirati Therapeutics (MRTX) | 3.0 | $11M | 193k | 58.75 |
|
|
Viking Therapeutics (VKTX) | 2.9 | $11M | 585k | 18.61 |
|
|
Rallybio Corp (RLYB) | 2.3 | $8.7M | 3.6M | 2.39 |
|
|
Tyra Biosciences (TYRA) | 2.0 | $7.7M | +34% | 555k | 13.85 |
|
Anaptysbio Inc Common (ANAB) | 2.0 | $7.7M | 358k | 21.42 |
|
|
Scpharmaceuticals (SCPH) | 2.0 | $7.5M | 1.2M | 6.27 |
|
|
Zentalis Pharmaceuticals (ZNTL) | 2.0 | $7.4M | 490k | 15.15 |
|
|
Spruce Biosciences (SPRB) | 1.8 | $6.9M | 2.4M | 2.93 |
|
|
Avidity Biosciences Ord (RNA) | 1.6 | $6.0M | 666k | 9.05 |
|
|
Cogent Biosciences (COGT) | 1.2 | $4.6M | 790k | 5.88 |
|
|
Mersana Therapeutics (MRSN) | 0.8 | $3.0M | 1.3M | 2.32 |
|
|
Homology Medicines (FIXX) | 0.7 | $2.8M | 4.5M | 0.61 |
|
|
Gh Research Ordinary Shares (GHRS) | 0.6 | $2.3M | 404k | 5.80 |
|
|
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.2 | $901k | 1.1M | 0.79 |
|
Past Filings by 5AM Venture Management
SEC 13F filings are viewable for 5AM Venture Management going back to 2019
- 5AM Venture Management 2023 Q4 filed Feb. 14, 2024
- 5AM Venture Management 2023 Q3 filed Nov. 14, 2023
- 5AM Venture Management 2023 Q2 filed Aug. 14, 2023
- 5AM Venture Management 2023 Q1 filed May 15, 2023
- 5AM Venture Management 2022 Q4 filed Feb. 14, 2023
- 5AM Venture Management 2022 Q3 filed Nov. 14, 2022
- 5AM Venture Management 2022 Q2 filed Aug. 15, 2022
- 5AM Venture Management 2022 Q1 filed May 16, 2022
- 5AM Venture Management 2021 Q4 filed Feb. 3, 2022
- 5AM Venture Management 2021 Q3 filed Nov. 15, 2021
- 5AM Venture Management 2021 Q2 filed Aug. 16, 2021
- 5AM Venture Management 2021 Q1 filed May 17, 2021
- 5AM Venture Management 2020 Q4 filed Feb. 16, 2021
- 5AM Venture Management 2020 Q3 filed Nov. 16, 2020
- 5AM Venture Management 2020 Q2 filed Aug. 5, 2020
- 5AM Venture Management 2020 Q1 filed April 29, 2020